Adicet Bio's Q2 Net Loss Widens
7:40AM ET 8/10/2022 MT NewswiresAdicet Bio (ACET) reported Q2 net loss Wednesday of $0.56 per diluted share, widening from a loss of $0.34 a year earlier. Analysts polled by Capital IQ...
Quotes Snapshot > ACET
Adicet Bio Inc ACET:NASDAQ
Last Price$14.30NASDAQ Closing Price as of 4:00PM ET 8/19/22
Today's Change-0.39(2.65%)
Bid (Size)$13.80 (5)
Ask (Size)$15.39 (3)
Day Low / High$13.86 - 14.50
Volume368.0 K
Read more news Recent News
Insider Sell: Adicet Bio
4:56PM ET 8/03/2022 MT NewswiresBlake Aftab, Chief Scientific Officer, on August 01, 2022, sold 6,968 shares in Adicet Bio (ACET) for $115,948. Following the Form 4 filing with the SEC,...
Adicet Bio Says FDA Grants Fast Track Designation for ADI-001 for Non-Hodgkin's Lymphoma
7:52AM ET 4/19/2022 MT NewswiresAdicet Bio (ACET) said Tuesday the US Food and Drug Administration has granted fast track designation to ADI-001, a CD20-targeted experimental medicine for...
SMBC Nikko Starts Adicet Bio at Outperform With $28 Price Target
1:41AM ET 3/31/2022 MT NewswiresAdicet Bio (ACET) has an average rating of buy and price targets ranging from $21 to $35, according to analysts polled by Capital IQ. (MT Newswires covers...
View all Commentary and Analysis
Adicet Bio, (ACET) Investor Presentation - Slideshow
11:48AM ET 8/12/2022 Seeking AlphaAdicet Bio: A First Take
12:05PM ET 7/22/2022 Seeking AlphaAdicet Bio (ACET) Investor Presentation - Slideshow
8:42AM ET 7/01/2022 Seeking AlphaHealthcare Sector Stock Performance Continues To Improve
7:15AM ET 6/30/2022 Seeking AlphaCompany Profile
Business DescriptionAdicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. View company web site for more details
| Address | 200 Berkeley Street Boston, Massachusetts 02116 |
| Phone | +1.650.503.9095 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/11/2022 SC 13D/A |
| President, CEO, Secretary & Director | Chen Schor |
| Chief Financial Officer | Brian Nicholas Harvey |
| Chief Medical Officer & Senior Vice President | Francesco Galimi |
| Chief Technology Officer | Donald Healey |
Company Highlights
| Price Open | $14.38 |
| Previous Close | $14.69 |
| 52 Week Range | $6.25 - 21.17 |
| Market Capitalization | $572.4 M |
| Shares Outstanding | 40.0 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.37 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -140.90% |
| Return on Equity | -16.98% |
Analyst Ratings as of 04/07/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |